Two cases of Marburg virus disease, a hemorrhagic fever almost as deadly as Ebola, have been recorded in Ghana, the very first in the country, health authorities announced on Sunday.
• Read also: Guinea announces a case of Lassa fever in the South
• Read also: Côte d’Ivoire: Ebola case detected in Abidjan, “extremely worrying”, according to WHO
• Read also: Guinea: a first case of the virulent Marburg virus, the first in West Africa
On July 8, blood samples from two people taken in the Ashanti region (south) suggested the Marburg virus and the samples had been sent to the Pasteur Institute in Dakar (IDP) for confirmation, the Health Service said. Ghanaian (GHS).
“Additional testing at IDP, Senegal has corroborated the results,” Dr. Patrick Kuma-Aboagye, chief executive of GHS, said in a statement on Sunday.
“This is the first time that Ghana has confirmed (the presence of) the Marburg virus,” he said.
The 98 people identified as contact cases are currently in quarantine, the statement added, adding that no other case from Marburg has yet been detected among them.
Health authorities say they are doing everything to “protect the health of the population”, calling for cooperation “from everyone” so that the virus is “effectively contained”.
Marburg virus disease is transmitted to humans by fruit bats and spreads among humans through direct contact with bodily fluids of infected people, or with surfaces and materials, according to the World Health Organization. Health (WHO).
The WHO announced in September 2021 the end of the first episode of the Marburg virus in West Africa, 42 days following the identification of a single case in Guinea.
Sporadic outbreaks and cases had in the past been reported elsewhere in Africa, including South Africa, Angola, Kenya, Uganda and the Democratic Republic of Congo.
The disease begins suddenly, with high fever, intense headaches and possible malaise. Case fatality rates have ranged from 24% to 88% in previous outbreaks, depending on virus strain and case management, according to the WHO.
Although there are no approved vaccines or antiviral treatments to treat the virus, oral or intravenous rehydration and treatment for specific symptoms improves survival rates.
